VA
BCYC

Verdad Advisers’s Bicycle Therapeutics BCYC Stock Holding History

Verdad Advisers’s Portfolio BCYC Stock Details BCYC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$217K Buy
+51,100
New +$234K 0.21% 147

Other funds holding BCYC

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
GP
GSK plc London $602M AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Verdad Advisers's BCYC Position: Q2 2026 in Review

Verdad Advisers opened a new position in Bicycle Therapeutics (BCYC) in Q2 2026: 51,100 shares worth $217K. The stake represents 0.21% of the portfolio and ranks #147 among its holdings.

104 funds tracked by Wall St. Rank hold BCYC as of Q2 2026.

  • Verdad Advisers held 51,100 shares of Bicycle Therapeutics worth $217K as of Q2 2026.
  • Bicycle Therapeutics was a new Verdad Advisers position in Q2 2026.
  • Bicycle Therapeutics made up 0.21% of Verdad Advisers's portfolio in Q2 2026, its #147 holding.
  • 104 funds tracked by Wall St. Rank held Bicycle Therapeutics as of Q2 2026.

Based on Verdad Advisers's 13F filing for Q2 2026, filed 14 Aug 2026.